SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gilead Science (GILD) Followers
GILD 124.70-0.8%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: joarel who wrote (682)8/28/2002 10:18:07 AM
From: tuck  Read Replies (2) of 961
 
From Briefing.com:

>>9:20AM Gilead Sciences initiated with Sell rating at Fulcrum (GILD) 33.20: Fulcrum initiates coverage with a SELL rating and price target of $24; rating is based on the following factors: 1) anticipates modest sales growth of AmBisome and Viread due to increased competition, 2) Viread may also be limited by the emergence of viral resistance, 3) Adefovir will likely be approved by FDA but mkt expectations are too aggressive, and 4) unwarranted valuation.<<

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News